Interested in stem cell developments.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In the world of Big Pharma if you set things up right you can set your price, as well.
"Convalescent plasma reduces mortality by 35%" is wrong and way overstates its success.
There are studies looking at Convalescent Plasma given with other meds. RLF100 is likely to add to any CP benefit.
Even though you didn't say what Trump would endorse?
Dr. Sanjay Gupta is right now saying it is known Trump will push Convalescent Plasma.
One sad but very likely outcome is that some of those now holding a stock that gets mentioned with resulting great, possibly life-changing, profits will become so ecstatic they will want to party and will feel so confident and excited that they will down play or ignore safety precautions and end up getting COVID-19.
Yes! The My Pillow Guy says it is fantastic!!!!!!
Yes, looks good to me.
Relief Therapeutics has an Ameircan arm: NeuroRx in Wilmington, DE.
I don't think it is a matter of deserving recognition. It is a case of how much money can be made.
It is, however, possible that Relief Therapeutics has, on that issue, the right blend of political and financial connections (i.e. Dr, Javitt, among others).
"Every other country in the world has a three-stage process for approving and pricing prescription drugs. Governments first ask if the drug is safe. If the answer is yes, it asks if the drug is effective.
If the drug passes those two hurdles, most governments then ask how much more effective the new drug is compared to existing medicines. This efficacy calculation becomes the starting point for price negotiations, which usually involve threatening to keep the drug out of the country’s state-insured pool of medications if the company does not come up with a reasonable price.
The U.S. either skips or botches these steps. First, there is no regulatory review that determines comparative efficacy. In the U.S., the FDA review ends after the first two steps: Once a drug is deemed safe and effective, it goes on the market."
"If the medical condition is serious enough and the drug has no effective analog, companies can dictate their price."
"The business model for Big Pharma is brilliant. A substantial portion of research and development for new drugs is funded by the state, which then punts its intellectual work to private companies, who are then allowed to extract maximum profits back from the same government, which has over decades formalized an elaborate process of negotiating against itself in these matters."
Current Trump HHS Secretary Alex Azar worked under George W. and Dr. Jonathan Javitt had roles in the Bush '41, Clinton, and Bush '43 administrations related to health care and national security. He also was appointed by President Bush to Chair Health Committee of President's Information Technology Advisory Committee (PITAC).
I like your logic here but you are, along with many others, making the assumption that Trump will have intelligent and sane reasons for whatever he says.
It could also be the My Pillow guy announcing he will be putting RLF100 in his pillows.
Looks like 2004 to me.
Excellent presentation.
In a preceding study they used a jet nebuliser UNI light LC star® from PARI, Starnberg, Germany.
I mention this because a recent posting of the current 20 top inhaler makers includes PARI but not NEBU-TEC which made the ultrasonic nebulizer used in the second study but both studies were done back around 2008.
Just noting they here used an ultrasonic nebuliser, theOptineb®-ir; from NEBU-TEC, Elsenfeld, Germany.
What about the likelihood that the inhaled RLF100 will quickly, directly and very effectively go to exactly where it is needed, the alveolar sacs, thus may not need the higher concentration of the IV dosing.
Patience is a virtue but not when you are dying of COVID. I would think that in this atmosphere the peer review process could be accelerated a bit. That is to say by making sure the peer reviewers start their job right away, etc, without at all compromising the high standards of the review process.
I have been thinking that mentions of Trump saying something about RLFTF were really stretching it but I have now changed my mind and think this info makes it a real possibility.
They will take it down a bit to create a worry wart weekend and hope they get some sells Monday a.m..
Dated July 25, 2020
BRK-A has $146B in cash and a Market Cap of $204Billion. How does Apple get to over $2Trillion in comparison?
My own opinion is that with patients as sick as those recently treated with RLF-100 the data will confirm
there is no placebo factor.
You mean you think dividends are the reason Apple has become a $2 Trillion company?
If the pps went to $50 that would be a market cap of $100 Billion. These days not such a big deal. Apple is now a $2 Trillion company and no iPhone, not even the next one, will cure COVID-19.
I also have to agree with you guys on this issue.
If the pps went to $50 that would be a market cap of $100 Billion. These days not such a big deal.
Apple is now a $2 Trillion company and no iPhone, not even the next one, will cure COVID-19.
If the pps went to $50 that would be a market cap of $100 Billion. These days not such a big deal.
Apple is now a $2 Trillion company and no iPhone, not even the next one, will cure COVID-19.
We could conclude that the past few days and maybe tomorrow are seen by the relatively Big Money guys as their last chance to knock this stock down in a major way and pick up some nice chunks of shares at a very low price. That seems reasonable...............but could be wrong.
RELIEF THERAPEUTICS HOLDING SA Announces Plans to Test Aviptadil for Treatment of COVID-induced Acute Respiratory Distress Syndrome
https://infomeddnews.com/relief-therapeutics-holding-sa-announces-plans-to-test-aviptadil-for-treatment-of-covid-induced-acute-respiratory-distress-syndrome/
Thanks for you analysis. I will give it a closer look.
Extending the Overall Survival monitoring from 3 to 4 years seems very significant. Good work finding this.
3 Reasons Geron Corporation Stock Could Be a Big Winner @themotleyfool #stocks $GERN, $JNJ
https://www.fool.com/investing/2018/08/06/3-reasons-geron-corporation-stock-could-be-a-big-w.aspx
Bankers Quit Goldman, Citigroup for Biotech Riches https://finance.yahoo.com/news/bankers-quit-goldman-citigroup-biotech-220000679.html?soc_src=social-sh&soc_trk=tw
Bankers Quit Goldman, Citigroup for Biotech Riches https://finance.yahoo.com/news/bankers-quit-goldman-citigroup-biotech-220000679.html?soc_src=social-sh&soc_trk=tw